Gene methylation IBD Eligibility MALT Stricture Upper gastrointestinal tract 18 FDG-PET/CT Drug Resistance Disease Progression Rituximab plus chlorambucil Crohn's disease Methylation Venous thromboembolism RISK MORTALITY Screening Tailored therapy T1118 translocation Over 80s CARCINOGENESIS Epigenetics Inclusion Endoscopic treatment Crohn’s disease Rituximab Immune cells Therapeutics Consensus Neoadjuvant chemotherapy Original Article Clinical Gènes MICROBIOTA Acceptability Parvimonas micra Inflammatory bowel diseases Immunosuppressant Intestinal crypts Vedolizumab Disease progression Alkylating agents DNA methylation Ulcerative colitis Résistance IL23 Colon Méthylation HIV Cell adhesion Bacteria Colon cancer PCR Anti-TNF Microbiota Effectiveness Clinical guidelines Inflammatory bowel disease Microbiote Thérapie ciblée Dysbiosis Eradication Cancer Survival Clinical trial Inflammatory Bowel Diseases Dysbiose Inhibitor Helicobacter pylori Safety Disability Colorectal cancer Bactéries Kidney diseases Anti-TNF agents Algorithm Contraindication Primary sclerosing cholangitis Tuberculosis Biomarker Genes Epigénétiques Ustekinumab Cost effectiveness Colonic epithelial primary cells Gene expression COLON-CANCER Patient-reported outcome Biologics Colorectal cancer Colibactin and lipids Maintenance therapy Patients experience Monitoring Fecal microbiota Small molecules Colectomy IL12 MARKER Heart disease risk factors Surgery DNA METHYLATION